Praveen Tyle - Orient Europharma Independent Director
| 4120 Stock | TWD 41.40 1.85 0.00% |
Director
Mr. Praveen Tyle was serving as Independent Director in Orient Europharma Co., Ltd. since June 5, 2002. He holds a Ph.D. in Pharmacy from Ohio State University, the United States. He used to serve as Vice PresidentGlobal Pharmaceutical Sciences in Pharmacia Corporationrationration, Group Vice PresidentGlobal Pharmaceutical Sciences Manufacturing in Biovail Corporationrationration, as well as Senior Vice President in RD Chief Scientific Officer in Baussh Lomb. He is also Executive Vice PresidentResearch and Development in Lexicon Pharmaceuticals, USA, as well as Board Member in EyeGate Pharmaceuticals Inc., USA. since 2002.
| Age | 57 |
| Tenure | 22 years |
| Professional Marks | Ph.D |
| Phone | 886 2 2755 4881 |
| Web | https://www.oepgroup.com |
Orient Europharma Management Efficiency
Orient Europharma's management efficiency ratios could be used to measure how well Orient Europharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dexun Huang | Feature Integration Technology | N/A | |
| Yiming Zheng | Feature Integration Technology | N/A | |
| Qichong Chen | Level Biotechnology | N/A | |
| Lifeng Shao | Level Biotechnology | N/A | |
| Xiting Wang | Level Biotechnology | N/A | |
| Dehui Yang | Sunmax Biotechnology Co | N/A | |
| Zhizhong Liu | United Radiant Technology | N/A | |
| Xuanjin Li | Sunmax Biotechnology Co | N/A | |
| Zhifeng Lu | Sunmax Biotechnology Co | N/A | |
| Jingji Wu | Asmedia Technology | N/A | |
| Yongfeng Zhang | Level Biotechnology | N/A | |
| Laifu Guo | Sunmax Biotechnology Co | N/A | |
| Changde Ni | United Radiant Technology | N/A | |
| Zeren Huang | Sunmax Biotechnology Co | N/A | |
| Zhida Yan | Feature Integration Technology | N/A | |
| Zhewei Lin | Asmedia Technology | N/A | |
| Hsu Ted | Asmedia Technology | N/A | |
| Quan Lin | Sunmax Biotechnology Co | N/A | |
| Jiangyuan Chen | United Radiant Technology | N/A | |
| Zengwen Chen | Feature Integration Technology | N/A | |
| Jintong Li | Level Biotechnology | N/A | |
Management Performance
| Return On Equity | -0.0268 | |||
| Return On Asset | -0.0027 |
Orient Europharma Leadership Team
Elected by the shareholders, the Orient Europharma's board of directors comprises two types of representatives: Orient Europharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orient. The board's role is to monitor Orient Europharma's management team and ensure that shareholders' interests are well served. Orient Europharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orient Europharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Praveen Tyle, Independent Director | ||
| Anita Chen, Head of Corporate Public Affairs | ||
| Jianming Tan, General Manager-Southeast Asia Area Nutrition & Health Business | ||
| Liann Lai, Director Division | ||
| Menglin Cai, Deputy General Manager-Management, Operation and Support Center, Director | ||
| Jiaxiu Lin, General Manager-Greater China Area Nutrition & Health Business | ||
| Zhiping Zhang, General Manager-Western Medicine | ||
| Jack Wu, Director | ||
| Wende Wang, Director | ||
| Jinzeng Lu, General Manager-Western Medicine Brand Development & New Business Division | ||
| Jizhou Liao, Director | ||
| Junjie Wu, General Manager-Nutrition & Health Care, Director | ||
| Phoebe Lee, Chief Officer | ||
| Zhenghong Cai, Chairman of the Board, CEO | ||
| Jing Tsai, Chairman of the Board | ||
| Yuling Li, CFO | ||
| Huaming Lin, Independent Director | ||
| Mon Tsai, General Manager, Director | ||
| Shufen Lin, Director | ||
| Yanjuan Chen, Head of Corporate Public Affairs | ||
| Peter Tsai, CEO Chairman |
Orient Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orient Europharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0268 | |||
| Return On Asset | -0.0027 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 5.9 B | |||
| Shares Outstanding | 86.75 M | |||
| Shares Owned By Insiders | 65.10 % | |||
| Shares Owned By Institutions | 0.45 % | |||
| Price To Book | 1.07 X | |||
| Price To Sales | 0.68 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Orient Europharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Orient Europharma's short interest history, or implied volatility extrapolated from Orient Europharma options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Orient Europharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Orient Stock analysis
When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |